Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400
Debt
Debt-to-Equity Ratio0.02
Current Ratio8.69
Quick Ratio8.69
Price-To-Earnings
Trailing P/E Ratio-35.62
Forward P/E Ratio-23.70
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.41 million
Price / Sales45.82
Cash FlowN/A
Price / CashN/A
Book Value$1.08 per share
Price / Book15.14
Profitability
EPS (Most Recent Fiscal Year)($0.47)
Net Income$-34,380,000.00
Net Margins-400.13%
Return on Equity-59.39%
Return on Assets-50.38%
Miscellaneous
Employees93
Outstanding Shares88,020,000
Market Cap$1.49 billion
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How were Arrowhead Pharmaceuticals' earnings last quarter?
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) posted its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.18) EPS for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.62 million. Arrowhead Pharmaceuticals had a negative net margin of 400.13% and a negative return on equity of 59.39%. View Arrowhead Pharmaceuticals' Earnings History.
When is Arrowhead Pharmaceuticals' next earnings date?
What price target have analysts set for ARWR?
6 brokers have issued twelve-month target prices for Arrowhead Pharmaceuticals' shares. Their forecasts range from $11.68 to $20.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $16.1967 in the next twelve months. This suggests that the stock has a possible downside of 0.9%. View Analyst Price Targets for Arrowhead Pharmaceuticals.
What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals.
What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and are raising our 12-month PT to $18/share from $13/share following 3Q18 financial and corporate updates from Arrowhead Pharmaceuticals. The company hosted a call and highlighted upcoming data presentations at AASLD (pending abstract acceptances) for two lead indications (ARO-HBV and ARO-AAT) and provided updates to additional TRiM candidates that are approaching or have already entered the clinic." (8/7/2018)
- 2. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)
Are investors shorting Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 13,603,112 shares, an increase of 10.3% from the July 13th total of 12,328,878 shares. Based on an average daily volume of 2,117,807 shares, the days-to-cover ratio is presently 6.4 days. Approximately 18.1% of the shares of the stock are short sold. View Arrowhead Pharmaceuticals' Current Options Chain.
Who are some of Arrowhead Pharmaceuticals' key competitors?
Some companies that are related to Arrowhead Pharmaceuticals include GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP) and Horizon Pharma (HZNP).
Who are Arrowhead Pharmaceuticals' key executives?
Arrowhead Pharmaceuticals' management team includes the folowing people:
- Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 49)
- Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 52)
- Dr. Bruce D. Given, Chief Operating Officer (Age 64)
- Mr. Patrick O'Brien, Gen. Counsel (Age 54)
- Mr. Peter B. Leone MBA, VP of Strategic Bus. Initiatives (Age 61)
Has Arrowhead Pharmaceuticals been receiving favorable news coverage?
Press coverage about ARWR stock has trended somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arrowhead Pharmaceuticals earned a coverage optimism score of 0.06 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 47.70 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Arrowhead Pharmaceuticals.
Who are Arrowhead Pharmaceuticals' major shareholders?
Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include RTW Investments LP (9.43%), BlackRock Inc. (8.09%), Schwab Charles Investment Management Inc. (0.52%), Bank of New York Mellon Corp (0.39%), Swiss National Bank (0.16%) and ClariVest Asset Management LLC (0.14%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.
Which institutional investors are selling Arrowhead Pharmaceuticals stock?
ARWR stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Alps Advisors Inc. and Bank of Montreal Can. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
Which institutional investors are buying Arrowhead Pharmaceuticals stock?
ARWR stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, BlackRock Inc., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Swiss National Bank, EAM Global Investors LLC, State of Wisconsin Investment Board and EAM Investors LLC. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
How do I buy shares of Arrowhead Pharmaceuticals?
Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arrowhead Pharmaceuticals' stock price today?
One share of ARWR stock can currently be purchased for approximately $16.35.
How big of a company is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals has a market capitalization of $1.49 billion and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe.
How can I contact Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]
MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
